Ironwood Pharmaceuticals (IRWD) Enterprise Value (2009 - 2026)

Ironwood Pharmaceuticals has disclosed Enterprise Value across 18 years of filings, most recently posting -$220.5 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$220.5 million, down 103.23% year-over-year; the trailing twelve-month figure through Mar 2026 was -$220.5 million (down 103.23% YoY), and the FY2025 annual result was -$215.5 million, down 143.29% from the prior year.
• Enterprise Value came in at -$220.5 million for Q1 2026 at Ironwood Pharmaceuticals, down from -$215.5 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$88.2 million in Q3 2024 to a low of -$741.6 million in Q1 2023.
• The 5-year median for Enterprise Value is -$140.4 million (2025), against an average of -$272.9 million.
• Across the five-year window, Enterprise Value surged 85.98% in 2023 and slumped 143.29% in 2025, its largest moves.
• Ironwood Pharmaceuticals' Enterprise Value stood at -$657.5 million in 2022, then soared by 85.98% to -$92.2 million in 2023, then grew by 3.9% to -$88.6 million in 2024, then sank by 143.29% to -$215.5 million in 2025, then dropped by 2.33% to -$220.5 million in 2026.
• The last three Enterprise Value figures came in at -$220.5 million (Q1 2026), -$215.5 million (Q4 2025), and -$140.4 million (Q3 2025), per Business Quant data.